bioAffinity Technologies Names Dallas J. Coleman as National Director of Sales
November 06 2023 - 8:00AM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF;
BIAFW), a biotechnology company focused on the need for
noninvasive, accurate tests for the detection of early-stage cancer
and lung disease, today announced the appointment of Dallas J.
Coleman as National Director of Sales. Mr. Coleman has more than 15
years of experience in medical sales and marketing, most recently
as Executive Account Manager for the respiratory portfolio of
Olympus America’s therapeutic solutions division.
Reporting to bioAffinity Technologies President and Chief
Executive Officer Maria Zannes, Mr. Coleman is responsible for
leading the CyPath® Lung sales team and sourcing new business
opportunities.
“We are delighted to welcome Dallas to our management team in
this newly created position. His experience and demonstrated track
record in building strong relationships with our target customers
and creating effective sales organizations is a timely and
strategic fit as we ramp up the commercialization of CyPath® Lung,
our noninvasive test for the detection of early-stage lung cancer,”
Ms. Zannes said. “As a near-term priority, his expertise in
developing commercial initiatives is expected to help drive the
expansion of our pilot market launch across Texas and pave the way
for the national rollout of CyPath® Lung.”
At Olympus America, Mr. Coleman was part of a team that launched
new products, including spiration valves for COPD and emphysema
patients, navigational bronchoscopy to access peripheral nodules,
and ultrasound bronchoscopes used to sample lymph nodes for cancer
staging, primarily marketing to pulmonologists, interventional
pulmonologists, thoracic surgeons and physicians treating patients
with lung disease. Prior to that, he held sales management
positions at Caldera Medical, a medical device company focused on
women’s health, and Ecolab, a global sustainability leader
providing water, hygiene and hospital infection prevention
solutions and services.
“My career has consistently revolved around extending the lives
of patients and improving their quality of life. For the past five
years, I have provided physicians and hospitals with innovative
devices for the diagnosis and treatment of pulmonary diseases,
including lung cancer,” Mr. Coleman said. “More than 14 million
Americans are at high risk for lung cancer, and the opportunity to
share CyPath® Lung with their care teams is highly motivating. I
look forward to working with my new colleagues at bioAffinity to
accelerate the rollout of this innovative product and help
physicians treat lung cancer in its early stages, with better
outcomes for patients.”
About CyPath® Lung
CyPath® Lung uses flow cytometry to identify cell populations in
patient sputum that indicate malignancy. Automated data analysis
developed using proprietary artificial intelligence can help
determine if cancer is present or if the patient is cancer-free.
CyPath® Lung incorporates a fluorescent porphyrin, TCPP, that is
preferentially taken up by cancer and cancer-related cells. In a
clinical trial, CyPath® Lung showed 92% sensitivity, 87%
specificity and 88% accuracy in detecting lung cancer in patients
at high risk for the disease who had small lung nodules less than
20 millimeters. Half of all patients in the trial who had cancer
were diagnosed in early Stages I or II. Diagnosing and treating
early-stage cancer can increase patient survival and improve
outcomes.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung and broad-spectrum cancer treatments. The Company’s first
product, CyPath® Lung, is a noninvasive test that has shown high
sensitivity, specificity and accuracy for the detection of
early-stage lung cancer. CyPath® Lung is marketed as a Laboratory
Developed Test (LDT) by Precision Pathology Laboratory Services, a
subsidiary of bioAffinity Technologies. Research and optimization
of the Company’s platform technologies are conducted in its
laboratories at Precision Pathology and The University of Texas at
San Antonio. For more information, visit www.bioaffinitytech.com
and follow us on LinkedIn, Facebook
and Twitter.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and
include statements regarding Mr. Coleman’s expected contributions,
including his expertise in developing commercial initiatives to
drive the expansion of the Company’s pilot market launch across
Texas, paving the way for the national rollout of CyPath® Lung,
bringing CyPath® Lung to market, and helping physicians treat lung
cancer in its early stages with better outcomes for patients. These
forward-looking statements are subject to various risks and
uncertainties, many of which are difficult to predict that could
cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the ability to successfully integrate Mr.
Coleman with the management team and derive the contributions
expected from him and the other factors discussed in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2022,
and its subsequent filings with the SEC, including subsequent
periodic reports on Forms 10-Q and 8-K. Such forward-looking
statements are based on facts and conditions as they exist at the
time such statements are made and predictions as to future facts
and conditions. While the Company believes these forward-looking
statements are reasonable, readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. The information in this release is provided only as of
the date of this release, and the Company does not undertake any
obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231106271829/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
Investor Relations Dave Gentry RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498 BIAF@redchip.com
bioAffinity Technologies (NASDAQ:BIAFW)
Historical Stock Chart
From Apr 2024 to May 2024
bioAffinity Technologies (NASDAQ:BIAFW)
Historical Stock Chart
From May 2023 to May 2024